Inventor · disambiguated record
Paul A. Moore
Also filed as: MOORE PAUL · MOORE PAUL A
75 granted patents·131 pending applications·1,256 citations·filing 1994–2025
99Inventor score
Top patents by PatentIndex Score
206 records- 0197US9822181B2Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereofMACROGENICS INC·Filed 2014·Granted Nov 21, 2017·62 cites·32 claims
- 0297US8802091B2Antibodies reactive with B7-H3 and uses thereofJOHNSON LESLIE S·Filed 2012·Granted Aug 12, 2014·54 cites·10 claims
- 0397US7968689B2Antibodies to HSDEK49 polypeptidesHUMAN GENOME SCIENCES INC·Filed 2008·Granted Jun 28, 2011·61 cites·17 claims
- 0496US9150656B2Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereofJOHNSON LESLIE S·Filed 2011·Granted Oct 6, 2015·47 cites·28 claims
- 0596US6472512B1Keratinocyte derived interferonHUMAN GENOME SCIENCES INC·Filed 2001·Granted Oct 29, 2002·59 cites·33 claims
- 0695US11623959B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2020·Granted Apr 11, 2023·6 cites·23 claims
- 0795US10633440B2Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·11 cites·18 claims
- 0895US10577422B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 3, 2020·19 cites·10 claims
- 0995US10160806B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2015·Granted Dec 25, 2018·18 cites·34 claims
- 1095US9896508B2Antibodies reactive with B7-H3 and uses thereofMACROGENICS INC·Filed 2016·Granted Feb 20, 2018·8 cites·12 claims
- 1195US8168586B1Cancer targets and uses thereofFANG DONG·Filed 2008·Granted May 1, 2012·40 cites·4 claims
- 1295US6475753B194 Human Secreted ProteinsHUMAN GENOME SCIENCES INC·Filed 1999·Granted Nov 5, 2002·108 cites·37 claims
- 1394US10787521B2Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereofMACROGENICS INC·Filed 2017·Granted Sep 29, 2020·7 cites·18 claims
- 1494US10647768B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2015·Granted May 12, 2020·19 cites·21 claims
- 1594US6861227B2Antibodies to cytokine receptor common gamma chain likeHUMAN GENOME SCIENCES INC·Filed 2002·Granted Mar 1, 2005·42 cites·96 claims
- 1693US11858991B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2021·Granted Jan 2, 2024·2 cites·18 claims
- 1793US9441049B2Antibodies reactive with B7-H3 and uses thereofMACROGENICS INC·Filed 2014·Granted Sep 13, 2016·10 cites·11 claims
- 1893US6476195B1Secreted protein HNFGF20HUMAN GENOME SCIENCES INC·Filed 2000·Granted Nov 5, 2002·47 cites·36 claims
- 1992US7842291B1Methods and compositions for diagnosing and treating diseasesCELERA CORP·Filed 2007·Granted Nov 30, 2010·14 cites·4 claims
- 2091US9714296B2Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereofMACROGENICS INC·Filed 2015·Granted Jul 25, 2017·7 cites·27 claims
- 2191US6569992B1Protein HLQDR48HUMAN GENOME SCIENCES INC·Filed 1999·Granted May 27, 2003·49 cites·52 claims
- 2290US9714295B2Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereofMACROGENICS INC·Filed 2015·Granted Jul 25, 2017·6 cites·27 claims
- 2390US6936691B2Secreted protein HCE3C63HUMAN GENOME SCIENCES INC·Filed 2001·Granted Aug 30, 2005·33 cites·22 claims
- 2490US6534631B1Secreted protein HT5GJ57HUMAN GENOME SCIENCES INC·Filed 2000·Granted Mar 18, 2003·20 cites·12 claims
- 2589US11685781B2Variant CD3-binding domains and their use in combination therapies for the treatment of diseaseMACROGENICS INC·Filed 2019·Granted Jun 27, 2023·4 cites·33 claims
- 2689US11459394B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2018·Granted Oct 4, 2022·4 cites·8 claims
- 2789US11384149B2Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereofMACROGENICS INC·Filed 2019·Granted Jul 12, 2022·4 cites·13 claims
- 2889US10683364B2Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereofMACROGENICS INC·Filed 2017·Granted Jun 16, 2020·3 cites·20 claims
- 2989US8143026B2Albumin fusion proteinsROSEN CRAIG A·Filed 2009·Granted Mar 27, 2012·11 cites·5 claims
- 3089US6693077B1Keratinocyte growth factor-2HUMAN GENOME SCIENCES INC·Filed 2000·Granted Feb 17, 2004·30 cites·48 claims
- 3189US6605592B2Protein HOFNF53HUMAN GENOME SCIENCES INC·Filed 2001·Granted Aug 12, 2003·36 cites·19 claims
- 3289US6420526B1186 human secreted proteinsHUMAN GENOME SCIENCES INC·Filed 1998·Granted Jul 16, 2002·82 cites·58 claims
- 3389US2024409661A1Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses ThereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 3488US11072653B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Jul 27, 2021·4 cites·17 claims
- 3588US10954301B2Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 23, 2021·3 cites·8 claims
- 3688US6525174B1Precerebellin-like proteinHUMAN GENOME SCIENCES INC·Filed 1998·Granted Feb 25, 2003·47 cites·19 claims
- 3788US6077692AKeratinocyte growth factor-2HUMAN GENOME SCIENCES INC·Filed 1998·Granted Jun 20, 2000·52 cites·683 claims
- 3887US11942149B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2022·Granted Mar 26, 2024·1 cites·14 claims
- 3987US8524238B2Cancer targets and uses thereofFANG DONG·Filed 2012·Granted Sep 3, 2013·5 cites·4 claims
- 4087US6433145B1Keratinocyte derived interferonHUMAN GENOME SCIENCES INC·Filed 2000·Granted Aug 13, 2002·28 cites·92 claims
- 4186US11098119B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2018·Granted Aug 24, 2021·2 cites·14 claims
- 4286US10633443B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·3 cites·9 claims
- 4385US10501552B2Multivalent molecules comprising DR5-binding domainsMACROGENICS INC·Filed 2015·Granted Dec 10, 2019·6 cites·26 claims
- 4485US6844170B1Cytokine receptor common gamma chain likeHUMAN GENOME SCIENCES INC·Filed 1999·Granted Jan 18, 2005·48 cites·34 claims
- 4585US6372473B1Tissue plasminogen activator-like proteaseHUMAN GENOME SCIENCES INC·Filed 1999·Granted Apr 16, 2002·47 cites·77 claims
- 4685US2024117036A1Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2023·Application pending·0 cites
- 4785US2024182559A1MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSMACROGENICS INC·Filed 2023·Application pending·0 cites
- 4884US11697684B2Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2020·Granted Jul 11, 2023·1 cites·13 claims
- 4984US11639386B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2020·Granted May 2, 2023·1 cites·10 claims
- 5084US7459531B250 Human secreted proteinsHUMAN GENOME SCIENCES INC·Filed 2006·Granted Dec 2, 2008·3 cites·5 claims
Showing the top 50 of 206 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Paul A. Moore files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →